<?xml version="1.0" encoding="UTF-8"?>
<p>The intention-to-treat (ITT) population will comprise all randomized participants who received a dose of a study vaccine and that have at least one post-vaccination blood sample. The per protocol (PP) population will include randomized participants who have a blood sample at baseline and 28 days (Â±3 days) post-vaccination, who are seronegative (PRNT 
 <sub>50</sub> &lt;1:10) to YF at baseline, and for whom the eligibility criteria were correctly applied. The safety population will include all subjects who received a study vaccine.
</p>
